What Ansa Biotechnologies does

Ansa Biotechnologies is a privately held biotechnology company founded in 2018 and headquartered in Emeryville, California, that has developed a proprietary enzymatic DNA synthesis platform for direct synthesis of double-stranded DNA without assembly-based methods. The technology removes constraints associated with traditional chemical synthesis, enabling direct synthesis of complex sequences containing repeats, GC-rich regions, homology arms, regulatory elements, and other features that other vendors reject or modify. Ansa's product portfolio spans three tiers: DNA Fragments (200–900 bp), Clonal DNA (100 bp–7.5 kb), and XL Clonal DNA (7.5–50 kb), with sequence accuracy verified by PacBio HiFi end-to-end sequencing and backed by an industry-first On-Time Guarantee. The company also operates an AI codon language model for sequence optimization and is a member of the International Gene Synthesis Consortium, screening all orders under the NSTC Framework for Nucleic Acid Synthesis Screening.

Ansa sells primarily through a direct e-commerce portal and direct enterprise sales, with a January 2026 strategic collaboration extending distribution through Integrated DNA Technologies (IDT), a Danaher company, for global market access. Customers include gene and cell therapy developers, antibody discovery researchers, contract development and manufacturing organizations (CDMOs), agrigenomics companies, and academic and nonprofit research institutions — including Hexagon Bio, the George Church Lab at Harvard Medical School and MIT, Terrain Bio, the Allen Institute's Seattle Hub for Synthetic Biology, the University of Maryland, and Applied StemCell. Pricing is per-order, quote-based, and varies by sequence complexity, length, and turnaround time, with standard ship times ranging from as few as 4 business days (fragments) to 25 business days (XL clones). Total funding raised exceeds $134 million, including a $68 million Series A led by Northpond Ventures in 2022 and a $54.4 million Series B led by Cerberus Ventures in October 2025.

Name

Ansa Biotechnologies

Legal name

Ansa Biotechnologies, Inc.

Website

https://ansabio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Ansa Biotechnologies is a private Emeryville, California biotech that offers enzymatic DNA synthesis services producing sequence-perfect DNA fragments, clonal DNA, and XL clonal constructs up to 50 kb for gene therapy, cell therapy, antibody discovery, CDMO, agrigenomics, and academic customers.

Ownership category

akta.pro rank

Product category

Synthetic DNA Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Enzymatic DNA synthesis
• Clonal DNA services
• Synthetic biology tools
• Gene synthesis platform
• DNA fragments manufacturing

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Custom DNA Synthesis Products: Direct sale of synthetic DNA products including Clonal DNA (up to 7.5 kb), XL Clonal DNA (7.5 kb to 50 kb), and DNA Fragments (200-900 bp). Customers place orders through Ansa's e-commerce portal or via sales engagement. Revenue is generated through per-order pricing based on sequence complexity and length.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Ansa Biotechnologies develops and sells custom synthetic DNA manufactured through a proprietary enzymatic DNA synthesis platform. The company directly synthesizes double-stranded DNA up to 50 kb without assembly-based methods, producing DNA Fragments (200-900 bp), Clonal DNA (100 bp to 7.5 kb), and XL Clonal DNA (7.5 kb to 50 kb) that are sequence-verified with PacBio HiFi sequencing and delivered under an industry-first On-Time Guarantee.

Product overview

Ansa Biotechnologies is a biotech company offering enzymatic DNA synthesis services through a unified platform that produces sequence-perfect synthetic DNA. The product portfolio centers on three main tiers: DNA Fragments (200-900 bp) for rapid fragment synthesis, Clonal DNA (100 bp – 7.5 kb) for sequence-verified cloned constructs, and XL Clonal DNA (7.5 kb – 50 kb) for extended-length applications. The platform is distinguished by its ability to directly synthesize complex sequences (high/low GC content, repeats, secondary structures, ITRs) that fail at other vendors, and is backed by an On-Time Guarantee service. Additional offerings include Catalog Vectors and a Custom Vector Early Access Program. Products are ordered through Ansa's e-commerce portal, with distribution also available through Integrated DNA Technologies (IDT) partnership.

Differentiator

Problem solved

Functional benefit

Products and services

• DNA Fragments Direct enzymatic synthesis of double-stranded DNA fragments from 200-900 bp, offering rapid turnaround and the ability to incorporate complex sequence features that challenge traditional chemical synthesis methods.
• Clonal DNA Direct enzymatic synthesis of double-stranded clonal DNA from 100 bp up to 7.5 kb, featuring sequence-perfect delivery of complex sequences including regulatory elements, homology arms, and repetitive domains that are often rejected elsewhere.
• XL Clonal DNA Extended-length clonal DNA synthesis service delivering sequence-verified constructs from 7.5 kb to 50 kb, enabling researchers to access full-length genes and large constructs without fragmentation or reassembly.
• Catalog Vectors Pre-designed cloning, bacterial, mammalian, AAV, and transcription vectors available for ordering alongside Ansa's custom DNA synthesis products.

Quantifiable outcome

• Complex repetitive sequences up to 41 kb successfully delivered that other companies declined to synthesize
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Foundation for American Innovation and Institute for ProgresscoreStrategic or Co-development Partner · 8 June 2026Ansa co-signed an open letter organized by these organizations urging Congress to mandate screening for synthetic DNA and RNA orders to prevent AI-designed bioweapons. This coalition included AI companies (OpenAI, Anthropic, Google DeepMind, Microsoft AI, Meta, Stripe) and other synthetic biology manufacturers (Twist Bioscience). The initiative calls for legally required screening and record-keeping across the synthetic genetic material industry.
• Integrated DNA Technologies (IDT)coreChannel Partner/ Reseller/ Distributor · 14 January 2026Strategic collaboration to expand IDT's synthetic biology portfolio with Ansa's Clonal DNA and XL Clonal DNA products (100 bp to 50 kb). The partnership enables IDT customers to access Ansa's enzymatic DNA synthesis platform for next-generation cell and gene therapy discovery, vaccine research, and agrigenomics applications. Ansa's products are exclusively manufactured in the United States. Jason T. Gammack, CEO of Ansa, stated the collaboration aims to overcome long-standing technical barriers in DNA synthesis, providing researchers with greater access to longer, more complex DNA constructs.
• Applied StemCellcoreStrategic or Co-development Partner · 11 November 2025Applied StemCell demonstrated efficient site-specific integration of a 50 kb DNA construct into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT technology, achieving greater than 20% efficiency at the H11 safe harbor locus. The 50 kb multifunctional construct was produced by Ansa Biotechnologies using enzymatic DNA synthesis and contains multiple expression cassettes enabling immune evasion and tunable gene expression. This milestone enables new applications in allogeneic cell therapy development, multi-protein complex expression, and stable viral vector manufacturing.
• International Gene Synthesis ConsortiumcoreStrategic or Co-development PartnerAnsa is a member of the International Gene Synthesis Consortium and adheres to their Harmonized Screening Protocol. All requested sequences are screened according to the NSTC Framework For Nucleic Acid Synthesis Screening before being synthesized.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Twist Bioscience: Twist is the leading commercial DNA synthesis provider serving synthetic biology, drug discovery, and academic customers. Ansa competes directly with Twist's gene fragments and clonal gene offerings, while Twist's silicon-based DNA synthesis platform is the dominant incumbent Ansa is attempting to disrupt enzymatically.
• GenScript: GenScript offers gene synthesis, cloning, and protein services to biotech and pharma customers globally. It is a direct peer in custom gene and clonal DNA synthesis, with broader service portfolio and a much larger installed customer base than Ansa.
• DNA Script: DNA Script is a direct enzymatic DNA synthesis competitor focused on benchtop enzymatic synthesizers and a commercial synthesis service. Both companies share the same novel-method architecture (enzymatic synthesis) and target the same biotechnology customer base.

Emerging players

• Synthego: Synthego provides synthetic biology tools including synthetic RNA, gene editing reagents, and cell engineering services. There is meaningful overlap in customer base (cell and gene therapy researchers) and product category (synthetic nucleic acids).
• Codex DNA: Codex DNA (formerly Synthetic Genomics) develops synthetic biology tools, including DNA assembly and protein engineering platforms. It overlaps with Ansa in providing synthetic DNA and engineered biological constructs to biotech and pharma researchers.
• Bota Bio: Bota Bio operates a synthetic biology platform developing engineered microbes and bioprocesses. It is an emerging player in the broader synthetic biology tooling space, with overlap in customer type (biotech and industrial biotech developers) but with a different product offering (whole-cell engineering vs. DNA synthesis).

Broad incumbents

• Agilent Technologies: Agilent provides genomics reagents, oligonucleotide synthesis, and molecular biology tools to a shared biotech and pharma customer base. Agilent is a broad incumbent in the DNA synthesis and molecular biology tools category.
• Eurofins Genomics: Eurofins Genomics is a large-scale provider of DNA synthesis, sequencing, and genotyping services globally. It is a broad incumbent addressable by customers with similar use cases (gene synthesis for academic and biotech research) but with a much broader portfolio than Ansa.
• Integrated DNA Technologies (IDT): IDT, a Danaher company, is both Ansa's strategic distribution partner and a broad incumbent in oligonucleotides, gene synthesis, and synthetic biology reagents. The two are comparable in customer base (gene therapy, vaccine research, agrigenomics) but IDT operates at significantly greater scale and breadth.
• Thermo Fisher Scientific (GeneArt): Thermo Fisher's GeneArt business offers gene synthesis, genome editing tools, and protein expression services. Ansa's COO previously scaled gene synthesis manufacturing at Thermo Fisher, and the company's offerings directly overlap with GeneArt's gene synthesis portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AnsaBio
• YouTubeyoutube.com/@ansabio
• LinkedInlinkedin.com/company/ansabio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ansa Biotechnologies